HSA
CHRS icon

Hussman Strategic Advisors’s Coherus Oncology CHRS Stock Holding History

Hussman Strategic Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,600
Closed -$201K – 332
2022
Q1 		$201K Hold
15,600
– – 0.04% 291
2021
Q4 		$249K Sell
15,600
-20,400
-57% -$357K 0.05% 289
2021
Q3 		$579K Hold
36,000
– – 0.13% 221
2021
Q2 		$498K Hold
36,000
– – 0.1% 263
2021
Q1 		$526K Buy
+36,000
New +$611K 0.11% 251

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Hussman Strategic Advisors's CHRS Position: Q2 2022 in Review

Hussman Strategic Advisors sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 15,600 shares — an estimated $201K sold.

Hussman Strategic Advisors first reported a position in CHRS in Q1 2021 and held it in 5 quarters. The position peaked at $579K in Q3 2021. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

  • Hussman Strategic Advisors reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
  • Hussman Strategic Advisors sold 15,600 Coherus Oncology shares in Q2 2022, an estimated $201K.
  • Hussman Strategic Advisors first reported a position in Coherus Oncology in Q1 2021 and held it in 5 quarters.
  • Hussman Strategic Advisors's Coherus Oncology position peaked at $579K in Q3 2021.
  • 176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Hussman Strategic Advisors's 13F filing for Q2 2022, filed 12 Sep 2022.